Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents

Izabela Strzeminska, Cécile Factor, Philippe Robert, Anne-Laure Grindel, Pierre-Olivier Comby, Joanna Szpunar, Claire Corot, Ryszard Lobinski

To cite this version:


HAL Id: hal-02481979
https://hal-univ-pau.archives-ouvertes.fr/hal-02481979

Submitted on 16 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License
Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents

Izabela Strzeminska, MS,*,† Cécile Factor, PhD,*,† Philippe Robert, PhD,*, Anne-Laure Grindel, MS,*,† Pierre-Olivier Comby, MD,‡ Joanna Szpunar, PhD, DSc,‡ Claire Corot, PharmD, PhD,*,† and Ryszard Lobinski, PhD, DSc†

Purpose: The aim of this study was to investigate the presence and chemical forms of residual gadolinium (Gd) in rat brain after a single dose of Gd-based contrast agent.

Methods: Four groups of healthy rats (2 sacrifice time-points, n = 10/group, 80 rats in total) were randomized to receive a single intravenous injection of 1 of the 3 Gd-based contrast agents (GBCAs) (gadoterate meglumine, gadobenate dimeglumine, or gadodiamide) or the same volume of 0.9% saline solution. The injected concentration was 0.6 mmol/kg, corresponding to a concentration of 0.1 mmol/kg in humans after body surface normalization between rats and humans (according to the US Food and Drug Administration recommendations). Animals were sacrificed at 2 washout times: 1 (M1) and 5 (M5) months after the injection. Total Gd concentrations were determined in cerebellum by inductively coupled plasma mass spectrometry. Gadolinium speciation was analyzed by size-exclusion chromatography coupled to inductively coupled plasma mass spectrometry after extraction from cerebellum.

Results: A single injection of a clinically relevant dose of GBCA resulted in the detectable presence of Gd in the cerebellum 1 and 5 months after injection. The cerebellar total Gd concentrations after administration of the least stable GBCA (gadodiamide) were significantly higher at both time-points (M1: 0.280 ± 0.060 nmol/g; M5: 0.193 ± 0.023 nmol/g) than those observed for macrocyclic gadoterate (M1: 0.019 ± 0.004 nmol/g, M5: 0.004 ± 0.002 nmol/g; P < 0.0001). Gadolinium concentrations after injection of gadobenate were significantly lower at both time-points (M1: < 0.0001). Gadolinium concentrations after injection of gadobenate were significantly higher at both time-points (M1: 0.019 ± 0.004 nmol/g, M5: 0.004 ± 0.002 nmol/g; P < 0.0001). Gadolinium concentrations after injection of gadobenate were significantly lower at both time-points (M1: 0.019 ± 0.004 nmol/g, M5: 0.004 ± 0.002 nmol/g; P < 0.0001). Gadolinium concentrations after injection of gadobenate were significantly lower at both time-points (M1: 0.019 ± 0.004 nmol/g, M5: 0.004 ± 0.002 nmol/g; P < 0.0001). Gadolinium concentrations after injection of gadobenate were significantly lower at both time-points (M1: 0.019 ± 0.004 nmol/g, M5: 0.004 ± 0.002 nmol/g; P < 0.0001). Gadolinium concentrations after injection of gadobenate were significantly lower at both time-points (M1: 0.019 ± 0.004 nmol/g, M5: 0.004 ± 0.002 nmol/g; P < 0.0001). Gadolinium concentrations after injection of gadobenate were significantly lower at both time-points (M1: 0.019 ± 0.004 nmol/g, M5: 0.004 ± 0.002 nmol/g; P < 0.0001). Gadolinium concentrations after injection of gadobenate were significantly lower at both time-points (M1: 0.019 ± 0.004 nmol/g, M5: 0.004 ± 0.002 nmol/g; P < 0.0001).

Conclusions: A single injection of a clinically relevant dose of GBCA is sufficient to investigate long-term Gd retention in the cerebellar parenchyma. Administration of linear GBCAs (gadodiamide and gadobenate) resulted in higher residual Gd concentrations than administration of the macrocyclic gadoterate. Speciation analysis of the water-soluble fraction of cerebellum confirmed washout of intact GBCA over time. The quantity of Gd bound to macromolecules, observed only with linear GBCAs, remained constant 5 months after injection and is likely to represent a permanent deposition.

Key Words: gadolinium-based contrast agent, cerebellum, gadolinium species, gadolinium retention, gadodiamide, gadobenate, gadoterate

Gadolinium (Gd)-based contrast agents (GBCAs) constitute a major research topic in the field of clinical magnetic resonance imaging (MRI). Since 2014, numerous clinical and preclinical studies have demonstrated increased signal intensity (SI) on unenhanced T1-weighted MRI images in specific structures of the healthy brain after repeated administrations of linear GBCAs.1–4 The quantitatively and qualitatively variable presence of Gd in cerebral parenchyma according to the molecular class of the GBCA was confirmed using inductively coupled plasma mass spectrometry (ICP-MS) and transmission electron microscopy–energy dispersive x-ray spectrometry.5,6 Gadolinium retention in the brain raises important safety concerns because of the acute and chronic toxicities of ionic Gd5–7 and its deleterious role in the pathophysiology of nephrogenic systemic fibrosis.8 Nephrogenic systemic fibrosis is an adverse reaction primarily related to administration of linear GBCAs in patients with severe renal disease.9

Two types of GBCAs are distinguished according to the chemical structure of the ligand associated with Gd: linear and macrocyclic GBCAs. An overview of various stability parameters of 3 GBCAs is presented in Table 1. Thermodynamic stability (which reflects the affinity of Gd for its ligand) and kinetic stability (which reflects the rate at which the equilibrium between the metal and its ligand is reached) are generally both used to describe the physicochemical characteristics of GBCAs.10 High kinetic stability provided by the macrocyclic structure minimize dechelation both in vitro and in vivo. Compared with macrocyclic GBCAs, linear chelates present moderate or poor kinetic stability with a higher likelihood of dechelation.11,12 Numerous clinical and preclinical studies have suggested that Gd retention in tissues is inversely correlated with the thermodynamic and kinetic stability of the GBCA injected.13–16 Thus, linear GBCAs result in more intense and more persistent Gd retention than macrocyclic GBCAs. Indeed, 2 studies of long-term elimination kinetics from the rat brain tissues showed rapid washout of Gd after repeated injections of macrocyclic GBCAs.14,16 Conversely large amount of Gd remained in the brain 1 year after the administration of the linear GBCAs. Gadolinium species present in the cerebellar parenchyma of rats have been studied by size-exclusion chromatography (SEC) coupled to ICP-MS. These studies also observed the first and fifth month, whereas the amount of Gd present in the macromolecular fraction remained constant 5 months after injection.

Received for publication July 10, 2019; and accepted for publication, after revision, August 24, 2019.

From the *Guerbet Research and Innovation Department, Aulnay-sous-Bois; †Analytical and Physical Chemistry for the Environment and Materials, IPREM–UMR 5254, CNRS, Université de Pau et des Pays de l’Adour (UPPA), E2S, Pau; and ‡Department of Neuroradiology, François-Mitterrand University Hospital, Dijon, France.

Conflicts of interest and sources of funding: I.S., C.F., P.R., A.L.G., and C.C. are employees of Guerbet. Correspondence to: Izabela Strzeminska, MS, Research and Innovation Department, Guerbet Group, BP57400, 95943 Roissy CDG Cedex, France. E-mail: izabela.strzeminska@guerbet.com.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 0020-9996/20/55030–0138
DOI: 10.1097/RLI.0000000000006223
demonstrated a class effect, resulting in presence of Gd species bound to soluble macromolecules only after repeated injections of linear GBCAs. In addition, the time-dependent elimination of Gd from the brain was associated with the clearance of the intact GBCA form. Although the clinical consequences of Gd retention have not yet been demonstrated, the European Medicines Agency has suspended all linear GBCAs in the European Union (with few exceptions for the liver indications). The US Food and Drug Administration (FDA) has acknowledged the presence of a GBCA class effect, but, as no toxicological effect has yet been associated with Gd retention, it decided not to suspend the use of linear GBCAs in the United States. However, the FDA requested changes in the package inserts with the same wording for all marketed GBCAs and invited GBCA manufacturers to conduct further studies to assess the safety of these agents.

The current knowledge of brain Gd retention is largely based on retrospective studies documented for patients who received multiple injections of GBCAs or using animal models that reproduce repeated injections of GBCAs. In addition, the time-dependent elimination of Gd from the brain was associated with the clearance of the intact GBCA form. Although the clinical consequences of Gd retention have not yet been demonstrated, the European Medicines Agency has suspended all linear GBCAs in the European Union (with few exceptions for the liver indications). The US Food and Drug Administration (FDA) has acknowledged the presence of a GBCA class effect, but, as no toxicological effect has yet been associated with Gd retention, it decided not to suspend the use of linear GBCAs in the United States. However, the FDA requested changes in the package inserts with the same wording for all marketed GBCAs and invited GBCA manufacturers to conduct further studies to assess the safety of these agents.

The current knowledge of brain Gd retention is largely based on retrospective studies documented for patients who received multiple injections of GBCAs or using animal models that reproduce repeated injection conditions. However, patients who occasionally undergo an MRI examination with injection of a GBCA must not be neglected. Few researchers have addressed the issue of residual Gd after injection of a single clinically relevant dose. Recently, Radbruch et al published laser ablation ICP-MS data comparing the amount and the distribution of the retained Gd and different Gd species from the cerebellar nuclei of a sheep after a single injection at a dose comparable to a human patient. These results revealed that after linear GBCAs administration, the mean Gd concentrations were between 58 ng Gd/g tissue and 167 ng Gd/g tissue in the deep cerebellar nuclei, whereas no significant difference of Gd concentrations between 3 marketed macrocyclic GBCAs and the control group was found. However, there is still a need for the investigation of the residual Gd and Gd speciation after a single injection of a clinically relevant dose of different GBCAs. Moreover, the evaluation of the total Gd and different Gd species should be done after a longer period than in the described publication (10 weeks). This study was therefore designed to provide the complete information about the identity of the chemical forms of the residual Gd 1 and 5 months after a single injection of a clinically relevant dose of 3 different GBCAs. In addition, the kinetics of elimination of different Gd species from the cerebellum was investigated.

**MATERIALS AND METHODS**

All animal experiments were conducted in full compliance with European Union Directive 2010/63/EU on the protection of animals used for scientific purposes.

---

**TABLE 1. Overview of the Various Parameters Reflecting the Stability of GBCAs**

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Generic Name</th>
<th>Type</th>
<th>Ionic/Nonionic</th>
<th>Excess Ligand</th>
<th>Log K_{ML}</th>
<th>Log K_{ML} pH = 7.4</th>
<th>Half-Lives T_{1/2} pH = 1</th>
<th>Half-Lives T_{1/2} pH &gt; 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dotarem</td>
<td>Gadoterate meglumine</td>
<td>Macrocyclic</td>
<td>Ionic</td>
<td>No</td>
<td>25.6</td>
<td>19.3</td>
<td>26.4 h (37°C)</td>
<td>37 y (pH = 5.3, 25°C)</td>
</tr>
<tr>
<td>MultiHance</td>
<td>Gadobenate dimeglumine</td>
<td>Linear</td>
<td>Ionic</td>
<td>No</td>
<td>22.6</td>
<td>18.4</td>
<td>&lt;5 s (25°C)‡</td>
<td>5–7 d (pH = 7.4, 25°C) C²</td>
</tr>
<tr>
<td>Omniscan</td>
<td>Gadodiamide</td>
<td>Linear</td>
<td>Nonionic</td>
<td>Cu-DTPA-BMA (Na⁺ salt) 5% (25 mmol/L)</td>
<td>16.9</td>
<td>14.9</td>
<td>&lt;5 s (25°C)‡</td>
<td>5–7 d (pH = 7.4, 25°C) C²</td>
</tr>
</tbody>
</table>

*The values of thermodynamic constants were taken from Port et al.
†The values of half-lives were taken from Frenzel et al, and were determined in absence of a biological matrix.
‡The same value was attributed for each linear GBCA, as the linear GBCA for which this parameter was determined was not specified.

---

Analytical reagent grade chemicals were used for this study. Ultrapure deionized water (18 MΩ cm) was obtained with the Milli-Q water purification system (Merck, Darmstadt, Germany).

**Animal Model and GBCA Administration**

Four groups of 9-week-old, healthy female Sprague-Dawley rats, each weighing between 214 and 290 g at the beginning of the study (SPF/OFA rats; Charles River, L’Arbresle, France, total of 80 rats, n = 10/group, 2 sacrifice time-points) randomly received a single intravenous injection of either a Gd-based contrast agent (0.6 mmol/kg, corresponding to 0.1 mmol/kg in humans after adjusting for body surface area according to FDA guidelines) or 0.9% saline solution (saline chaser was not used). To cover the various GBCA classes available on the global market, animals received an injection of a macrocyclic ionic GBCA (gadoterate meglumine, Dotarem; Guerbet, Villepinte, France), a linear ionic GBCA (gadobenate dimeglumine, MultiHance; Bracco, Milan, Italy), and a linear nonionic GBCA (gadodiamide, Omniscan; GE Healthcare, Chalfont St Giles, United Kingdom). These 3 GBCAs are characterized by different thermodynamic and kinetic stabilities. They were used in the form of the commercially available solution for injection (500 mM solutions). Intravenous injections (injection volume: 1.2 mL/kg) were performed in a tail vein under isoflurane anesthesia (IsoFlo; Axcience, Pantin, France). Animals were sacrificed at 2 washout time-points: 1 month and 5 months after injection, referred to as M1 and M5 throughout this article. For the long-term follow-up, the time-point of 5 months after the last GBCA administration was chosen according to Robert et al. At completion of each washout period, the rats were euthanized by exsanguination under isoflurane anesthesia. The brain was removed and dissected to sample a half cerebellum. Half cerebella were stored at −80°C before sample preparation. Special care was taken to avoid experimental Gd contamination between groups at each step of the study. Animals were raised by groups to protect against potential urine and feces contamination between groups (coprophagous species), as recommended elsewhere. Rats were always handled by using new gloves, including for cage changes. The entire procedure (injection, sacrificed, and tissue sampling) was performed per group, with disposable surgical drapes, gloves, gowns, masks, and tools.

**Sample Preparation**

One half of the cerebellum was homogenized using an UltraTurrax disperser (IKA-Werke GmbH & Co KG, Staufen, Germany) in water (dilution factor of 6) in an ice bath. The tissue homogenate was then centrifuged using the Centrifuge 5804 R (Eppendorf AG, Hamburg, Germany) for 60 minutes at 20,800 g at 4°C, and the supernatant was
Separated from the pellet. The supernatant was collected and stored at −80°C before speciation analysis by SEC coupled to ICP-MS. Aliquots of the homogenate, the supernatant, and the pellet were stored in −20°C before determination of the total Gd concentration in these fractions. The sample preparation procedure is outlined in Figure 1.

**Total Gd Determination**

Samples (either 100 μL or the whole pellet) were digested on a hot plate with a mixture (3:1, vol/vol) of nitric acid and hydrogen peroxide (either 400 μL or a volume calculated to respect the dilution factor of 5) at 80°C for 8 hours followed by dilution with water. In this last step, indium was added as internal standard to obtain 1 ng/mL final concentration. Total Gd concentrations were measured in a homogenate, a supernatant, and a pellet with ICP-MS using an Agilent Model 7500 or 7700x ICP MS (Agilent Technologies, Santa Clara, CA). The ICP-MS instrument used for total Gd determination was optimized daily using a multielemental solution. A standard curve of inorganic Gd in 4.2% HNO₃ was used by monitoring the response of the ¹⁵⁸Gd isotope. The quantification range of the method was 0.010 to 1.0 ng/mL in solution for the first time-point (M1) and 0.001 to 0.5 ng/mL for the second time-point (M5). The Gd concentration in each fraction of cerebellum (homogenate, supernatant, and pellet) was expressed as nanomole per gram and was calculated by multiplying the Gd concentration measured in the final solution by the dilution factor applied during sample preparation, including the homogenization step for calculation for the cerebellum. The corresponding lower limits of quantification (LLOQs) of Gd in the cerebellum were 0.018 nmol/g in wet tissue (M1) and 0.002 nmol/g in wet tissue (M5), complying with the criterion that the signal-to-noise ratio must be at least 5. To control for the background level of Gd, the supernatants obtained from the samples of the control group were run between the samples of the GBCA group as blanks. The average blank chromatogram per run was calculated (6 runs in total) and subtracted from the chromatograms of the corresponding runs of the GBCA groups. To evaluate the amount of water-soluble Gd extracted from the cerebellum and analyzed by SEC-ICP-MS, the extraction efficiency was calculated using the following equation: 

$$\text{extraction efficiency} = \frac{n_{\text{Gd supernatant}} + n_{\text{Gd pellet}}}{n_{\text{Gd homogenate}}}$$

where $n_{\text{Gd}}$ is the number of moles of Gd. In addition, the mass balance was verified using the following equation: 

$$\text{mass balance} = \frac{n_{\text{Gd homogenate}}}{n_{\text{Gd supernatant}} + n_{\text{Gd pellet}}}$$

**Statistical Analysis**

Data are expressed as mean ± standard deviation (SD). Due to the nonhomogeneous variance of total Gd concentrations, and the nonnormal distribution of some groups (D’Agostino-Pearson test), the differences between these data were analyzed using a Kruskal-Wallis test followed by a Dunn test. For calculation of means and SDs, and for statistical analysis of total Gd concentration in the cerebellum, values less than LLOQ were arbitrarily replaced by the LLOQ value. Outliers for all data were detected and excluded from the analysis according to the ROUT method (Q = 1%). Statistical analyses were carried out using GraphPad Prism 7 software (GraphPad Software Inc, San Diego, CA). Differences were considered significant at $P \leq 0.05$.

**RESULTS**

**Total Gd Determination**

Total Gd concentrations in the cerebellum are shown in Figure 2. At the 2 time-points, total Gd concentrations for gadodiamide, the least stable GBCA, were significantly higher than the concentration measured for gadoterate ($P < 0.0001$). Similarly, the highest Gd concentration was found for gadodiamide (M1: 0.280 ± 0.060 nmol/g; M5: 0.193 ± 0.023 nmol/g) followed by gadobenate dimeglumine (M1: 0.093 ± 0.020 nmol/g; M5: 0.067 ± 0.013 nmol/g). The lowest total Gd concentration was therefore detected for gadoterate meglumine (M1: 0.019 ± 0.004 nmol/g; M5: 0.004 ± 0.002 nmol/g). At both time-points, Gd concentrations after injection of gadobenate, a linear GBCA, were significantly lower ($P < 0.05$) than those measured after injection of gadodiamide. At M5, the Gd concentration after injection of gadoterate was significantly lower than that measured after injection of gadobenate ($P < 0.05$). A similar but nonsignificant trend was observed at M1, which could be due to the presence of 5 results situated below the LLOQ. Five months after a single injection of gadoterate meglumine, the Gd concentration decreased (0.004 nmol/g) and was...
cies eluting after 20.1 minutes should be associated with molecules eluting before 13.1 minutes should be larger than 80 kDa, whereas species was eluted at 26.4 minutes. According to column calibration, all species were not included in the mass balance calculation.

After injection of gadoterate, at both M1 and M5, only one Gd species was not the methodological approach reported by Frenzel et al.13 to investigate whether residual Gd in the rat brain remained constant 5 months after injection. Moreover, for both time-points, the proportion of the peak at 11.7 minutes was higher for gadodiamide than for gadobenate.

**TABLE 2. Gadolinium Extraction Efficiency of Soluble Fraction of Cerebellum**

<table>
<thead>
<tr>
<th>Contrast Agent</th>
<th>Type</th>
<th>Extraction Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gadodiamide dimeglumine</td>
<td>Linear</td>
<td>8 ± 1 (n = 10)</td>
</tr>
<tr>
<td>Gadobenate meglumine</td>
<td>Macrocyclic</td>
<td>70 ± 2 (n = 5)</td>
</tr>
<tr>
<td>Gadoterate meglumine</td>
<td>Macrocyclic</td>
<td>70 ± 2 (n = 5)</td>
</tr>
<tr>
<td>Gadodiamide</td>
<td>Linear</td>
<td>8 ± 1 (n = 10)</td>
</tr>
</tbody>
</table>

Differences in number of replicates are due to the fact that, for some samples, the Gd concentration in the supernatant was <LLOQ. Note that the LLOQ for the M5 point (0.002 nmol/g) was much lower than for M1 (0.018 nmol/g) because of a different ICP-MS system used.

**DISCUSSION**

This study was based on the methodological approach reported by Frenzel et al.13 to investigate whether residual Gd in the rat brain was present in the form of intact GBCA or in other chemical form(s) and Gd elimination from the brain parenchyma after repeated injections of GBCAs. These analytical approaches are based on tissue fractionation and analysis of the water-soluble fraction extracted from different parts of the brain by HPLC-ICP-MS. In these studies, SEC was used for the detection of Gd species. Size-exclusion chromatography allows separation of analytes mainly according to their hydrodynamic volume, although other nongeneric mechanisms may also be concurrently involved. Smaller molecules flow more slowly through the column because they penetrate into the pores of the stationary phase, whereas large molecules are rapidly eluted through the column because they do not enter the pores. Hydrophilic interaction liquid chromatography, which allows unambiguous detection of small and hydrophilic molecules such as intact GBCA, was also used in 2 studies.14,15 Hydrophilic interaction liquid chromatography ICP-MS therefore provides complementary information to SEC-ICP-MS, allowing identification of intact GBCA in the soluble fraction but was not used in current study. These techniques allow a better understanding of Gd speciation and Gd elimination from the brain parenchyma after repeated injections of GBCAs. This study demonstrates, for the first time, the presence of different Gd species in rat cerebellum after a single injection of a clinically relevant dose of macrocyclic versus linear GBCAs. Because of very low brain Gd concentration expected after a single dose of 0.6 mmol/kg of GBCA, special precautions were taken to control for smaller than 12 kDa. The signal observed for gadoterate therefore corresponds to low molecular weight molecules, such as the form of GBCA initially injected. This retention time is in good agreement with the retention time detected for the standard GBCA solution. For the linear GBCAs, SEC-ICP-MS analysis of the soluble fraction showed 2 significant Gd peaks eluted at 11.7 minutes and 26.4 minutes. Similar to gadoterate, the peaks eluting at 26.4 minutes could be attributed to the form of Gd chelate initially injected. The signal observed at 11.7 minutes was assigned to a fraction of Gd bound to macromolecules heavier than 80 kDa. Five months after injection, the SI of intact GBCA (retention time, 26.4 minutes) decreased for all 3 GBCAs. However, the Gd signal at 11.7 minutes, representing Gd bound to macromolecules and detected only for the linear GBCAs, seemed to have remained constant 5 months after injection. Moreover, for both time-points, the proportion of the peak at 11.7 minutes was higher for gadodiamide than for gadobenate.
the background level of Gd and to avoid cross-contamination at each step of the experimental work. The procedure used in this study proved to be robust for the analysis of a large number of complex biological samples containing trace levels of Gd. Regarding the outliers, one sample showed an extremely high Gd concentration, strongly suggesting a contamination during the experimental work for this sample. Some of the 5 other outliers may be due to the fact that, for the purpose of the statistical treatment, the LLOQ value was arbitrarily assigned to the concentrations below LLOQ, which may have induced “artificial” outliers by the ROUT test.

Our data are qualitatively consistent with the results of previous studies of repeated injections in rats\(^{13-18}\) and with the study of single dose injection of GBCAs in a large animal model (ie, sheep).\(^{23}\) Linear GBCAs lose more residual total Gd in the cerebellum than macrocyclic GBCAs. Gadolinium elimination between M1 and M5 is much faster for the macrocyclic GBCA gadoterate (79% decrease in total, elementary Gd concentration) than for the linear GBCAs gadobenate and gadodiamide, with a 28% and 31% decrease, respectively, which confirms previous findings.\(^{14,16}\) Analysis of Gd speciation in the soluble fraction 1 month after a single injection of linear GBCAs showed that Gd was present in at least 2 distinct chemical forms: (1) small molecules including intact GBCA, and (2) soluble macromolecules. As reported by Robert et al,\(^{14}\) we confirmed that the Gd detected in soluble macromolecules should be associated with the class of macromolecules larger than 80 kDa. However, we observed only one significant Gd species, whereas Robert et al reported 2 peaks. On the other hand, Frenzel et al suggested that only a single class of macro- molecules contained Gd, but with significantly higher molecular weights (200–300 kDa). The different number of Gd signals bound to macromolecules, detected on SEC-ICP-MS chromatograms, could be explained by the use of different chromatographic columns. In this study, we used the same type of stationary phase as that used by Frenzel et al, which is a composite of cross-linked agarose and dextran, whereas Robert et al used a stationary phase composed of silica. The difference in molecular weight of the macromolecular Gd fraction detected (80 vs 300 kDa) is probably due to the use of different molecular weight markers for column calibration. It should also be noted that if the nature of the molecular weight marker used for column calibration differs from that of the analyte, molecular weights cannot be accurately calculated.

Compared with the Gd speciation observed for linear GBCAs, Gd was only detected in the form of intact GBCA after a single injection of the macrocyclic GBCA gadoterate. As previously described,\(^{14}\) washout of the intact GBCA can be observed for all GBCAs between M1 and M5. In the present study, we report an 89% to 100% decrease of the levels of the intact GBCA. In contrast, the amount of Gd bound to soluble macromolecules observed for gadobenate and gadodiamide remained constant 5 months after injection of a single dose of GBCA. It is possible that this fraction of Gd generates the persistent SI enhancement observed on MRI images. Consequently, the binding of Gd to soluble macromolecules could maximize its relaxivity and produce visible SI enhancement despite the very low Gd concentration. Another key point is that the extraction efficiency varies for each GBCA, as reported elsewhere.\(^{13,15,26}\) After injection of macrocyclic GBCAs, Gd was mostly found in the soluble brain fraction in the form of low molecular-weight molecules (Frenzel et al), corresponding to the intact GBCA form (Gianolio et al). Conversely, after injection of linear GBCAs, Gd was largely found in the pellet. The least thermodynamically stable GBCA could therefore induce other Gd forms, which are less effectively extracted by the sample preparation protocol, as reflected by our data. Interestingly, the extraction efficiency at M1 decreases in the order of stability of the GBCA: gadoterate > gadobenate > gadodiamide (Port et al).\(^{10}\)

A limitation of this study is the fact that SEC-ICP-MS does not allow identification of the chemical nature of the macromolecules and cannot demonstrate whether the intact linear GBCA or transmetalated Gd\(^{3+}\) ion is bound to macromolecules. This information would represent a substantial progress toward a better understanding of the processes involved in Gd accumulation in brain and the putative biological and toxicological consequences of this phenomenon. Frenzel et al\(^{13}\) suggested that intact GBCAs (except for gadobenate) do not bind to macromolecules because they do not bind to plasma proteins. Furthermore, a study comprising 15-day incubation of GBCAs in human serum showed release of 20% of free Gd\(^{3+}\) from nonionic linear GBCAs and 2% from ionic linear GBCAs, whereas no Gd release was reported for macrocyclic GBCAs.\(^{11}\) Although these findings strongly support the theory of potential dechelation of linear GBCAs, no evidence is available concerning the chemical form of Gd bound to macromolecules.

The second limitation of this study is that the speciation method only provides information about the water-soluble fraction. The insoluble fraction (pellet) that contains a large amount of Gd (especially for linear GBCAs) cannot be analyzed in terms of speciation. The pellet contains cell debris, inorganic precipitates such as colloidal forms of hydroxide, phosphate, and carbonate or denatured macromolecules, which could bind Gd or capture GBCAs. Research into solving this problem is already underway.

**CONCLUSIONS**

Even a single injection of a clinically relevant dose of Gd-based contrast agent resulted in long-term Gd detection in the cerebellar parenchyma of healthy rats. Administration of linear GBCAs (gadodiamide and gadobenate) resulted in higher residual Gd concentrations than...
administration of the macrocyclic agent gadoterate (15-fold higher at M1 to 48-fold higher at M5 for gadobenate vs gadoterate, 5-fold higher at M1 to 17-fold higher at M5 for gadobenate vs gadodiamide). Speciation analysis of the water-soluble fraction of cerebellum confirmed washout of the intact GBCA form with time. The amount of Gd bound to macromolecules, only observed with the linear GBCA, remained constant 5 months after injection and likely represents a permanent deposition.

REFERENCES


20. Food and Drug Administration. FDA drug safety communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body, requires new class warnings. Available at: https://www.fda.gov/drugs/drugsafety/ucm589213.htm. Accessed March 5, 2019.


